Internal Medicine, Texas A&M University Health Science Center, Temple, TX 76508, USA.
Department of Biology, University of Mary Hardin-Baylor, Belton, TX 76513, USA.
Cells. 2019 Sep 5;8(9):1031. doi: 10.3390/cells8091031.
The use of non-optimal preparations of mesenchymal stem cells (MSCs), such as extensively expanded cells, might be necessary to obtain the large numbers of cells needed for many clinical applications. We previously demonstrated that minimally expanded (early passage) MSCs can be pre-activated as spheroids to produce potentially therapeutic factors in 3D cultures. Here, we used extensively expanded (late passage) MSCs and studied their 3D-culture activation potential. MSCs were culture-expanded as 2D monolayers, and cells from various passages were activated by 3D culture in hanging drops with either fetal bovine serum (FBS)-containing media or a more clinically-applicable animal product-free (xeno-free) media. Gene expression analyses demonstrated that MSC spheroids prepared from passage 3, 5, and 7 cells were similar to each other but different from 2D MSCs. Furthermore, the expression of notable anti-inflammatory/immune-modulatory factors cyclooxygenase-2 (PTGS2), TNF alpha induced protein 6 (TNFAIP6), and stanniocalcin 1 (STC-1) were up-regulated in all spheroid preparations. This was confirmed by the detection of secreted prostaglandin E2 (PGE-2), tumor necrosis factor-stimulated gene 6 (TSG-6, and STC-1. This study demonstrated that extensively expanded MSCs can be activated in 3D culture through spheroid formation in both FBS-containing and xeno-free media. This work highlights the possibility of activating otherwise less useable MSC preparations through 3D culture generating large numbers of potentially therapeutic MSCs.
使用非最佳的间充质干细胞(MSCs)制剂,例如广泛扩增的细胞,可能是获得许多临床应用所需的大量细胞所必需的。我们之前证明,最小扩增(早期传代)的 MSCs 可以被预先激活为球体,以在 3D 培养中产生潜在的治疗因子。在这里,我们使用了广泛扩增(晚期传代)的 MSCs,并研究了它们的 3D 培养激活潜力。MSCs 被培养为 2D 单层,来自不同传代的细胞通过在含胎牛血清(FBS)的培养基或更具临床应用价值的无动物源(无异种)培养基的悬滴中进行 3D 培养而被激活。基因表达分析表明,来自第 3、5 和 7 代细胞的 MSC 球体彼此相似,但与 2D MSCs 不同。此外,所有球体制备物中抗炎/免疫调节因子环氧化酶-2(PTGS2)、肿瘤坏死因子诱导蛋白 6(TNFAIP6)和 STC-1 的表达均上调。这通过检测到分泌的前列腺素 E2(PGE-2)、肿瘤坏死因子刺激基因 6(TSG-6)和 STC-1 得到证实。这项研究表明,广泛扩增的 MSCs 可以通过在含 FBS 和无异种源的培养基中形成球体在 3D 培养中被激活。这项工作突出了通过 3D 培养生成大量潜在治疗性 MSCs 来激活其他不太可用的 MSC 制剂的可能性。
Curr Protoc Stem Cell Biol. 2014-2-6
Biochem Biophys Res Commun. 2019-12-24
Stem Cells Transl Med. 2025-3-18
Stem Cell Res Ther. 2023-12-18
Stem Cells Transl Med. 2022-4-29
J Tissue Eng Regen Med. 2022-1
Front Cell Dev Biol. 2021-3-19
Stem Cell Reports. 2021-4-13
Tissue Eng Part B Rev. 2018-10-27
Trends Mol Med. 2018-8-25
Cytotherapy. 2018-2-9
Stem Cells Transl Med. 2017-10-26
Proc Natl Acad Sci U S A. 2016-10-18
Stem Cell Res Ther. 2016-8-31